| 摘要 |
<p>The present invention relates to modified human chorionic gonadotrophin (β-hCG) proteins and their medical use as immunological contragestatives. The modification causes a reduction in the cross-reactivity of the modified β-hCG protein with LH as defined by the ability of both proteins to react with the same antibody.</p> |
